SORA

Advancing, promoting and sharing knowledge of health through excellence in teaching, clinical practice and research into the prevention and treatment of illness

Nox Inhibitors & Therapies: Rational Design of Peptidic and Small Molecule Inhibitors.

Cifuentes-Pagano, ME; Meijles, DN; Pagano, PJ (2015) Nox Inhibitors & Therapies: Rational Design of Peptidic and Small Molecule Inhibitors. Curr Pharm Des, 21 (41). pp. 6023-6035. ISSN 1873-4286 https://doi.org/10.2174/1381612821666151029112013
SGUL Authors: Meijles, Daniel

[img]
Preview
PDF Accepted Version
Available under License ["licenses_description_publisher" not defined].

Download (881kB) | Preview

Abstract

Oxidative stress-related diseases underlie many if not all of the major leading causes of death in United States and the Western World. Thus, enormous interest from both academia and pharmaceutical industry has been placed on the development of agents which attenuate oxidative stress. With that in mind, great efforts have been placed in the development of inhibitors of NADPH oxidase (Nox), the major enzymatic source of reactive oxygen species and oxidative stress in many cells and tissue. The regulation of a catalytically active Nox enzyme involves numerous protein-protein interactions which, in turn, afford numerous targets for inhibition of its activity. In this review, we will provide an updated overview of the available Nox inhibitors, both peptidic and small molecules, and discuss the body of data related to their possible mechanisms of action and specificity towards each of the various isoforms of Nox. Indeed, there have been some very notable successes. However, despite great commitment by many in the field, the need for efficacious and well-characterized, isoform-specific Nox inhibitors, essential for the treatment of major diseases as well as for delineating the contribution of a given Nox in physiological redox signalling, continues to grow.

Item Type: Article
Additional Information: The published manuscript is available at EurekaSelect via http://www.eurekaselect.com/openurl/content.php?genre=article&doi=10.2174/1381612821666151029112013].
Keywords: Disease, Drug Design, Enzyme Inhibitors, Humans, NADPH Oxidases, Oxidative Stress, Peptides, Small Molecule Libraries, Humans, Disease, Peptides, Enzyme Inhibitors, Oxidative Stress, Drug Design, Small Molecule Libraries, NADPH Oxidases, NADPH oxidase, Nox, inhibitors, peptides, small molecules, therapeutics, 1115 Pharmacology And Pharmaceutical Sciences, Medicinal & Biomolecular Chemistry
SGUL Research Institute / Research Centre: Academic Structure > Molecular and Clinical Sciences Research Institute (MCS)
Journal or Publication Title: Curr Pharm Des
ISSN: 1873-4286
Language: eng
Dates:
DateEvent
3 December 2015Published
27 October 2015Accepted
Publisher License: Publisher's own licence
Projects:
Project IDFunderFunder ID
R01HL079207NHLBI NIH HHSUNSPECIFIED
P01 HL103455NHLBI NIH HHSUNSPECIFIED
R01 HL112914NHLBI NIH HHSUNSPECIFIED
P01HL103455NHLBI NIH HHSUNSPECIFIED
R01 HL079207NHLBI NIH HHSUNSPECIFIED
PubMed ID: 26510437
Web of Science ID: WOS:000366196200010
Go to PubMed abstract
URI: http://sgultest.da.ulcc.ac.uk/id/eprint/108896
Publisher's version: https://doi.org/10.2174/1381612821666151029112013

Actions (login required)

Edit Item Edit Item